| PFE |
Report |
Adjusted EPS |
BEAT |
pred ~$0.73 vs. cons $0.68 |
MEDIUM |
| PFE |
Report |
Total Revenue |
IN-LINE |
pred ~$14.5B vs. cons $14.4B |
MEDIUM |
| PFE |
Report |
Ex-COVID / Launched-&-acquired revenue growth |
BEAT |
pred ~+7% op ($3.2B basket) vs. cons ~+5% |
LOW |
| PFE |
Guide |
FY26 Adjusted EPS guidance |
UNCHANGED |
guide ~$2.80-3.00 (mid $2.90) vs. cons $2.98 (FY26) |
MEDIUM |
| PFE |
Guide |
FY26 Revenue guidance |
UNCHANGED |
guide ~$59.5-62.5B (mid $61.0B) vs. cons $61.2B (FY26) |
MEDIUM |
| PFE |
Guide |
Capital allocation / buyback signal & dividend safety |
UNKNOWN |
guide ~$0.43/qtr div maintained, buyback back in consideration vs. cons no repurchase assumption (2H26) |
LOW |
| PFE |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.5% |
— |
MEDIUM |
| PFE |
Return |
5-day cumulative residual |
+0.0% (FADE) |
A cost-driven EPS beat with only a reaffirmed (not raised) FY26 guide and COVID-seasonal, LOE-pressured revenue gives no upward out-period revision fuel; implicit second-half math and durable LOE/COVID-erosion concerns pull estimates back down, so an initial pop on the beat and ~7% yield support tends to fade toward flat over five days absent a pipeline/obesity catalyst. |
MEDIUM |